Flotufolastat F 18 Pregnancy and Breastfeeding Warnings
Brand names: Posluma
Flotufolastat F 18 Pregnancy Warnings
This drug is not indicated for use in female patients.
US FDA pregnancy category: Not Assigned.
Risk summary: No data available on use of this drug in pregnant women to inform a drug-related risk.
Comments:
-Radioactive drugs have the potential to cause fetal harm.
Animal studies have not been reported. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Flotufolastat F 18 Breastfeeding Warnings
This drug is not indicated for use in female patients.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments:
-The effects in the nursing infant or on milk production are unknown.
See also
References for pregnancy information
- (2023) "Product Information. Posluma (flotufolastat F-18)." Blue Earth Diagnostics Inc.
References for breastfeeding information
- (2023) "Product Information. Posluma (flotufolastat F-18)." Blue Earth Diagnostics Inc.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
